Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) EVP Sells $38,837.34 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) EVP Masaru Matsuda sold 1,219 shares of Arcutis Biotherapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $38,837.34. Following the transaction, the executive vice president owned 111,289 shares of the company’s stock, valued at $3,545,667.54. The trade was a 1.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Masaru Matsuda also recently made the following trade(s):

• On Wednesday, November 4th, Masaru Matsuda sold 40,000 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $34.32, for a total value of $1,372,800.00.
• On Wednesday, September 16th, Masaru Matsuda sold 3,674 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $91,850.00.
• On Tuesday, September 8th, Masaru Matsuda sold 9,989 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $25.03, for a total transaction of $250,024.67.

Arcutis Biotherapeutics Stock Down 5.4%

Shares of Arcutis Biotherapeutics stock opened at $25.55 on Friday. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 0.46. The company has a fifty day moving average price of $27.16 and a 200 day moving average price of $25.37. Arcutis Biotherapeutics, Inc. has a twelve month low of $19.30 and a twelve month high of $34.80. The stock has a market cap of $3.21 billion, a price-to-earnings ratio of 121.67 and a beta of 1.66.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.12). The business had revenue of $143.92 million for the quarter, compared to the consensus estimate of $142.59 million. Arcutis Biotherapeutics had a net margin of 6.15% and a return on equity of 15.05%. Equities research analysts forecast that Arcutis Biotherapeutics, Inc. will post 0.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and set a $39.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, October 8th. Weiss Ratings raised Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 29th. Wall Street Zen lowered Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Morgan Stanley lifted their target price on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Needham & Company LLC set a $40.00 price target on Arcutis Biotherapeutics in a research note on Thursday. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Arcutis Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $39.75.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of large investors have recently made changes to their positions in ARQT. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Arcutis Biotherapeutics during the third quarter worth about $36,000. Allworth Financial LP raised its holdings in shares of Arcutis Biotherapeutics by 158.2% during the 3rd quarter. Allworth Financial LP now owns 2,089 shares of the company’s stock valued at $55,000 after purchasing an additional 1,280 shares in the last quarter. Nykredit A S acquired a new stake in Arcutis Biotherapeutics during the second quarter worth $63,000. Integrated Wealth Concepts LLC bought a new stake in shares of Arcutis Biotherapeutics during the second quarter worth $84,000. Finally, Sterling Capital Management LLC raised its stake in shares of Arcutis Biotherapeutics by 839.3% in the 3rd quarter. Sterling Capital Management LLC now owns 3,776 shares of the company’s stock valued at $100,000 after purchasing an additional 3,374 shares during the period.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.